

# Supplementary Materials: Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

Michael P. Lux, Naiba Nabieva, Andreas D. Hartkopf, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Diethelm Wallwiener, Andreas Schneeweiss and Sara Y. Brucker

Supplementary Table S1. Data categories captured in the PRAEGNANT study.

| Data Continuously Captured, if Applicable | Data Assessed at Study Entry            | Data Assessed at Follow-Up Care Appointments |
|---|---|--|
| Concomitant diseases                      | Life status, ECOG                       | Life status, ECOG                            |
| Concomitant medication                    | Quality of life                         | Quality of life                              |
| Cancer systemic therapies                 | Breast cancer risk factor questionnaire | Breast and axilla evaluation                 |
| Cancer radiotherapy                       | Breast and axilla evaluation            | Distant metastasis evaluation                |
| Cancer surgery                            | Distant metastasis evaluation           | Biomaterial ascertainment                    |
| Breast cancer right side                  | Biomaterial ascertainment               | PRO questionnaires                           |
| Breast cancer left side                   | PRO questionnaires                      |  |

ECOG, Eastern Cooperative Oncology Group (performance status); PRO, patient-reported outcome.